CBD of Denver, Inc. (CBDD) Advances Evaluation of AI-Driven Health & Wellness Acquisition Opportunity
Denver, Colorado--(Newsfile Corp. - June 30, 2026) - CBD of Denver, Inc. (OTCID: CBDD) ("CBDD" or the "Company") today announced that it has entered the due diligence phase with respect to a prospective acquisition in the health and wellness sector. As part of the Company's ongoing acquisition plans, management has reviewed a number of businesses spanning artificial intelligence, technology, consumer products, and health and wellness. Through this process, the Company identified an oper
Cannabis, Health, Cannabis Extractor, Cannabis Manufacturer
2026-06-30 9:46 AM EDT | CBD of Denver Inc.
Apptly's UberDoc Accelerates Growth Through Emphera Health Partnership, Adding Approximately 2,000 Specialists to the UberDoc Network
Vancouver, British Columbia--(Newsfile Corp. - June 30, 2026) - Apptly Health Technologies Corp. (CSE: APPT) (FSE: 4KL0) (the "Company"), operator of the UberDoc direct-pay healthcare marketplace ("UberDoc"), today announced that it has entered into a Strategic Collaboration Agreement with Emphera Health Holdings, Inc. dba Emphera Health ("Emphera Health"), a network that connects self-funded employers to outpatient surgical care, for an initial three year term, effective
2026-06-30 8:00 AM EDT | Apptly Health Technologies Corp.
TempraMed Expands Strategic Partnership with McKesson Medical-Surgical to Accelerate North American Growth and Launch Full Portfolio Across B2B Channels
Toronto, Ontario--(Newsfile Corp. - June 30, 2026) - TempraMed Technologies Ltd. (CSE: VIVI) (FSE: 9DY) ("TempraMed" or the "Company"), a leader in temperature-controlled medication solutions, is pleased to announce the expansion of its relationship with McKesson Medical-Surgical ("MMS"). The agreement, dated June 23, 2026, broadens the scope of collaboration to include full portfolio distribution across North America, enhanced B2B capabilities, and deeper integration into one of the la
Technology, Biotechnology, Pharmaceuticals, Health
2026-06-30 3:05 AM EDT | TempraMed Technologies Ltd.
Elite Pharmaceuticals, Inc. Reports Financial Results for the Fiscal Year Ended March 31, 2026 and Provides Conference Call Information
Northvale, New Jersey--(Newsfile Corp. - June 29, 2026) - Elite Pharmaceuticals, Inc. (OTCQB: ELTP) ("Elite" or the "Company"), a specialty pharmaceutical company developing niche generic products, announced results for the fiscal year ended March 31, 2026 ("Fiscal 2026"). Consolidated revenues for Fiscal 2026 were $148.9 million, an increase of $64.8 million or approximately 77% as compared to the comparable period of the prior fiscal year. Income from operations was $49.1 million
Healthcare and Hospitals, Pharmaceuticals, Health
2026-06-29 4:29 PM EDT | Elite Pharmaceuticals, Inc.
BUNCHIES Named Official Snack of The UNDERRATED Golf Tour
Los Angeles, California--(Newsfile Corp. - June 29, 2026) - BUNCHIES, the golf snack from Hally Leadbetter, today announces a new partnership with UNDERRATED Golf, the purpose-driven junior golf tour founded by four-time NBA Champion, two-time MVP and Olympic gold medalist Stephen Curry. BUNCHIES will serve
Food / Beverages, Sports, Health
2026-06-29 10:44 AM EDT | Bunchies
Beckett's Announces Resignation of CEO and Appointment of Interim CEO
Ontario and Los Angeles, California--(Newsfile Corp. - June 29, 2026) - Beckett's Inc. (CSE: BKTS) ("Beckett's" or the "Company") announces that Larry Weintraub has resigned as Chief Executive Officer and as a director of the Company, effective immediately. The Company has appointed Manish Z. Kshatriya, the Company's current Chief Financial Officer, as Interim Chief Executive Officer. Mr. Kshatriya will continue to serve as Chief Financial Officer. In connection w
Food / Beverages, Cannabis, Health
2026-06-29 8:22 AM EDT | Becketts Inc.
TempraMed Signs Non-Binding LOI with National Distributor in Saudi Arabia
Toronto, Ontario--(Newsfile Corp. - June 26, 2026) - TempraMed Technologies Ltd. (CSE: VIVI) (FSE: 9DY) ("TempraMed" or the "Company"), a medical-technology innovator transforming how temperature-sensitive medications are stored and managed, is pleased to announce that it has signed a non-binding letter of intent ("LOI") dated June 16, 2026 with Rawafed Health International Company ("Rawafed"), a leading healthcare distribution company with broad reach across pharmacy networks a
Technology, Biotechnology, Pharmaceuticals, Health
2026-06-26 4:10 PM EDT | TempraMed Technologies Ltd.
ScaleHealth.ca Launches Turnkey Recovery Layer for Health & Wellness Brands, Starting with DR-HO's
Toronto, Ontario--(Newsfile Corp. - June 26, 2026) - ScaleHealth.ca activates its Branded Clinical Hub model, giving health & wellness brands an instant, co-branded recovery access layer without infrastructure, hiring, or compliance overhead. Now live with DR-HO's existing traffic: providing virtual assessments, product education, partner services & incremental revenue, with zero clinical build required. Brands route
2026-06-26 4:08 PM EDT | Scale Health Network Inc.
Hemostemix Closes $360,000 First Tranche of Private Placement
Calgary, Alberta--(Newsfile Corp. - June 26, 2026) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) ("Hemostemix" or the "Company") is pleased to announce it has closed the first tranche of its previously announced non-brokered private placement of units (the "Offering"), as originally disclosed on June 17, 2026. The Company raised aggregate gross proceeds of CDN$360,000 under the first tranche through the issuance of 7,200,000 units ("Units") at
Biotechnology, Pharmaceuticals, Health
2026-06-26 8:47 AM EDT | Hemostemix Inc.
Charlotte's Web Provides Update on Diverging Hemp Policies: Federal Momentum Builds as California Restricts Therapeutic Hemp Product Access
Louisville, Colorado--(Newsfile Corp. - June 26, 2026) - Charlotte's Web Holdings, Inc. (TSX: CWEB) (OTCQX: CWBHF) ("Charlotte's Web" or the "Company"), a botanical wellness innovation company and a market leader in hemp wellness, today provided an update on developments pulling federal and state hemp policy in opposite directions. California restriction effective July 1, 2026 New California requirements under SB 378 and related state regulations will sig
2026-06-26 7:21 AM EDT | Charlotte's Web Holdings, Inc.
QScreen AI Announces Adoption of Semi-Annual Reporting
Toronto, Ontario--(Newsfile Corp. - June 26, 2026) - QScreen AI Inc. (CSE: QAI) (OTC Pink: PMEDF) (FSE: 3QP) ("QScreen" or "QAI"), an innovator in physiological AI screening, intelligence platform for clinical and occupational health applications, announces that it has elected to voluntarily adopt semi-annual financial reporting and rely on the exemptions in Coordinated Blanket Order 51-933 - Exemptions to Permit Semi-Annual Reporting for Certain Venture Issuers ("CBO 51-933"). Introduc
2026-06-26 7:02 AM EDT | QScreen AI Inc.
Phio Pharmaceuticals Announces Participation in the Renmark Financial Communications Live Virtual Non-Deal Roadshow Series
King of Prussia, Pennsylvania--(Newsfile Corp. - June 26, 2026) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage siRNA biopharmaceutical company developing therapeutics using its proprietary INTASYL® gene silencing technology to eliminate cancer. Phio Pharmaceuticals announced today that Robert Bitterman, CEO and Chairman of the Board, will present an overview of the Company's INTASYL® siRNA platform, including its lead clinical candidate PH-762
Biotechnology, Healthcare and Hospitals, Pharmaceuticals, Health
2026-06-26 7:00 AM EDT | Phio Pharmaceuticals Corp.
Medexus Announces Fiscal Year 2026 Results, Demonstrating Continued Momentum and Strong Product-Level Performance of GRAFAPEX (treosulfan) for Injection
Ontario and Chicago, Illinois--(Newsfile Corp. - June 25, 2026) - Medexus Pharmaceuticals (TSX: MDP) (OTCQX: MEDXF) today announced its operating and financial results and provided a business update for the company's fourth fiscal quarter and fiscal year ended March 31, 2026 (the company's fiscal Q4 2026 and fiscal year 2026). All dollar amounts in this news release are in US dollars unless specified otherwise. Company overview Medexus is currently focused on deliv
Biotechnology, Healthcare and Hospitals, Pharmaceuticals, Health
2026-06-25 6:00 PM EDT | Medexus Pharmaceuticals Inc.
Mobile-health Network Solutions Announces Effective Date of Reverse Stock Split
Singapore, Singapore--(Newsfile Corp. - June 25, 2026) - Mobile-health Network Solutions (NASDAQ: MNDR) ("MNDR" or the "Company"), a leading AI-powered digital health platform, today announced a one-for-six reverse stock split (the "Reverse Stock Split") of the Company's Class A Ordinary Shares ("Class A Ordinary Shares") will become effective at 12:01 a.m. Eastern Time on Monday, June 29, 2026. The Class A Ordinary Shares will continue to trade under its ex
2026-06-25 9:00 AM EDT | Mobile-health Network Solutions
AAMI Returns to Costa Rica with Advanced QMSR Course for Medical Device Professionals
Arlington, Virginia--(Newsfile Corp. - June 25, 2026) - Building on a partnership launched five years ago to strengthen the region's world-class medical device sector, the Association for the Advancement of Medical Instrumentation (AAMI) is returning to Costa Rica this August with a three-day course on FDA's Quality Management System Regulation. "Design and Development - Navigating and Implementing QMSR" will be held from August 25-27, 2026, offering medical device industry professional
2026-06-25 8:50 AM EDT | Association for the Advancement of Medical Instrumentation
BetterLife Engages Syner-G to Oversee GMP Manufacturing of BETR-001 for IND and Phase 1
Vancouver, British Columbia--(Newsfile Corp. - June 25, 2026) - BetterLife Pharma Inc. (CSE: BETR) (OTCQB: BETRF) (FSE: NPAU) ("BetterLife" or the "Company") announces it has entered into an agreement with Syner-G BioPharma Group ("Syner-G") to oversee GMP manufacturing of BETR-001 for its planned IND and Phase 1 program. BETR-001 is 2-bromo-lysergic acid diethylamide (2-Br-LSD), a non-hallucinogenic derivative of LSD. BETR-001 is active against neuroreceptors involved in
2026-06-25 8:00 AM EDT | BetterLife Pharma Inc.
QScreen AI Announces Close of First Tranche of Private Placement
Toronto, Ontario--(Newsfile Corp. - June 25, 2026) - QScreen AI Inc. (CSE: QAI) (OTC Pink: PMEDF) (FSE: 3QP) ("QScreen" or "QAI"), an innovator in physiological AI screening, intelligence platform for clinical and occupational health applications, is pleased to announce the closing of the first tranche of its previously announced non-brokered private placement. The Company is pleased to announce that it has completed the first tranche of its previously announced non-brokered private pla
2026-06-25 7:01 AM EDT | QScreen AI Inc.
Phio Pharmaceuticals Announces "How siRNA Therapy can Change the Course of Cancer Treatment" in a Fireside Chat with Force Family Office on Monday, June 29, 2026
King of Prussia, Pennsylvania--(Newsfile Corp. - June 25, 2026) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage siRNA biopharmaceutical company developing therapeutics using its proprietary INTASYL® gene silencing technology to eliminate cancer. Phio announced today that Mr. Robert Bitterman, CEO and Chairman of the Board, Phio Pharmaceuticals will participate in a fireside chat with Harvey Briggs, Chief Communications Officer, Force Family Office. Joining the
Biotechnology, Healthcare and Hospitals, Pharmaceuticals, Health
2026-06-25 7:00 AM EDT | Phio Pharmaceuticals Corp.
Custom Health Announces Strategic Leadership Appointments to Support Continued Growth and Regulatory Excellence
Robert Guzman has been appointed Chief Compliance & Regulatory Officer, bringing extensive experience in regulatory oversight, compliance management, and quality assurance to strengthen Custom Health's governance framework and support the Company's continued expansion across highly regulated healthcare and pharmacy markets. Brent Herman, Founder, President and Chief Executive Officer of InnovativeRx US Holdings, Inc., has been appointed Executive Vice President, Cor
Technology, Pharmaceuticals, Health
2026-06-25 6:30 AM EDT | Custom Health Holdings Inc.
Dr. Christina Rahm and DRC Ventures Accept Prestigious Gold Stevie(R) Award for Patent-Driven Manufacturing Innovation
New York, New York--(Newsfile Corp. - June 24, 2026) - Dr. Christina Rahm, founder and CEO of DRC Ventures, was honored with a Gold Stevie® Award at the 2026 American Business Awards® ceremony in New York City for her groundbreaking work in developing the patent-driven manufacturing infrastructure
Biotechnology, Food / Beverages, Health
2026-06-24 1:20 PM EDT | DRC Ventures